27, February 2015:
IVF technology advances have reached a brand-new level, with the UK's
parliament voting fiercely in favour of brand-new laws in the nation to
permit the production of IVF embryos with mitochondrial DNAfrom
a 3rd benefactor, so in addition to the nuclear DNA originating from an
embryo's two parents, a small amount of DNA would also come from a
third parent. The new technique will allow couples to utilize IVF for
the conception of kids, who otherwise would have inherited mortifying
mitochondrial or other genetic diseases.
MedicalNewsToday
has published an article revealing how genetic scientists have made use
of a new strategy that permits the whole genome of IVF embryos to be
scanned via the cells of 10 biopsies. The researchers say the testing is
the very first to be able to detect all the new genetic mutations that
happen distinctively in an individual, instead of just those that have
been handed down from parents. The development allows the whole genetic
code to be scanned for "potentially harmful" mutations, however more
work is had to fathom the exact disease consequences, according to the
Genome Research Journal, who confirm that the whole-genome sequencing
outcomes were analysed from cell biopsies removed from 2 individual
embryos from the very same couple.
According to the study, the strategy indicates the 5-day-old, blastocyst-stage embryos could be scanned, in a research initially, for "de novo mutations," those arising spontaneously in the egg or sperm and not passed down from either parent. This, the authors state, enhances the power of whole-genome screening to spot the diseases that may befall test-tube infants. Dr. Brock Peters and Dr. Radoje Drmanac, from Complete Genomics, the firm based in Mountain View, CA, that has actually developed the screening technology, are amongst the study authors. They have in fact stated... "This is the first demonstration that a large bulk of single-base de novo mutations, which trigger a disproportionally high percentage of genetic defects, can be detected in pre-implantation genetic medical diagnosis."
On the other hand, the report says, the pre-implantation genetic medical diagnosis that is utilized in fertility centres can find just the big chromosomal abnormalities or genetic mutations that are passed on to in vitro-fertilized (IVF) embryos by their parents. Using up to just 10 cells to do the whole-genome sequencing indicates the DNA has to be amplified, which can introduce errors, according to the study results, nevertheless, Drs. Peters and Drmanac, working with other commercial researchers from Complete Genomics and from Reprogenetics, did use the strategy at the NYU Fertility Centre to eliminate any falsely recognized genetic mutations.
The authors conclude their paper by stating their results recommend that whole-genome sequencing utilizing bar-coded DNA could be made use of in the future as part of the pre-implantation genetic medical diagnosis procedure to make best use of comprehensiveness in finding disease-causing mutations and minimize the occurrence of genetic diseases. It has recently been announced that for the 2nd time since 2013, the World Congress of Human Reproduction has entrusted the IVF-Spain Foundation to organize a satellite event on genetic innovations applied to fertility. World class speakers shall be presenting their latest works, such as Professor Nathan Treff, Director of Molecular Biology Research in Gynaecology and Obstetrics at the Robert Wood Johnson Medical School, Santiago Munna, avant-garde of pre-implementation genetic screening and preconception screening, as well as Professor Jose Horcajadas, world specialist in endometrial receptivity. The event will be held in Berlin, from the 18th of March till the 21st of March, 2015.
For Media Contact:
Company: Ivf-Spain S.L.
Full Address: Avda. de Ansaldo,
13, 03540, Alicante, Spain
Telephone Number: +34 965 267 890
Email: ivftreatmentspain@gmail.com
Website: www.ivf-spain.com
Video Youtube: https://www.youtube.com/watch?v=m17UCJhaOGA
According to the study, the strategy indicates the 5-day-old, blastocyst-stage embryos could be scanned, in a research initially, for "de novo mutations," those arising spontaneously in the egg or sperm and not passed down from either parent. This, the authors state, enhances the power of whole-genome screening to spot the diseases that may befall test-tube infants. Dr. Brock Peters and Dr. Radoje Drmanac, from Complete Genomics, the firm based in Mountain View, CA, that has actually developed the screening technology, are amongst the study authors. They have in fact stated... "This is the first demonstration that a large bulk of single-base de novo mutations, which trigger a disproportionally high percentage of genetic defects, can be detected in pre-implantation genetic medical diagnosis."
On the other hand, the report says, the pre-implantation genetic medical diagnosis that is utilized in fertility centres can find just the big chromosomal abnormalities or genetic mutations that are passed on to in vitro-fertilized (IVF) embryos by their parents. Using up to just 10 cells to do the whole-genome sequencing indicates the DNA has to be amplified, which can introduce errors, according to the study results, nevertheless, Drs. Peters and Drmanac, working with other commercial researchers from Complete Genomics and from Reprogenetics, did use the strategy at the NYU Fertility Centre to eliminate any falsely recognized genetic mutations.
The authors conclude their paper by stating their results recommend that whole-genome sequencing utilizing bar-coded DNA could be made use of in the future as part of the pre-implantation genetic medical diagnosis procedure to make best use of comprehensiveness in finding disease-causing mutations and minimize the occurrence of genetic diseases. It has recently been announced that for the 2nd time since 2013, the World Congress of Human Reproduction has entrusted the IVF-Spain Foundation to organize a satellite event on genetic innovations applied to fertility. World class speakers shall be presenting their latest works, such as Professor Nathan Treff, Director of Molecular Biology Research in Gynaecology and Obstetrics at the Robert Wood Johnson Medical School, Santiago Munna, avant-garde of pre-implementation genetic screening and preconception screening, as well as Professor Jose Horcajadas, world specialist in endometrial receptivity. The event will be held in Berlin, from the 18th of March till the 21st of March, 2015.
For Media Contact:
Company: Ivf-Spain S.L.
Full Address: Avda. de Ansaldo,
13, 03540, Alicante, Spain
Telephone Number: +34 965 267 890
Email: ivftreatmentspain@gmail.com
Website: www.ivf-spain.com
Video Youtube: https://www.youtube.com/watch?v=m17UCJhaOGA
No comments:
Post a Comment